[1]
Parasrampuria S, and Murphy S. Trends in Prescription Drug Spending, 2016-2021. Washington, DC: Office of the Assistant Secretary for Planning
and Evaluation, U.S. Department of Health and Human Services. September 2022.
[2]
Bosworth A, Sheingold S, Finegold K, De Lew N, Sommers BD. (Issue Brief No. HP-2022-27). Washington, DC: Office of the Assistant Secretary
for Planning and Evaluation, U.S. Department of Health and Human Services. September 30, 2022.
[3]
H.R.5376 - Inflation Reduction Act of 2022117th Congress (2021-2022) https://www.congress.gov/bill/117th-congress/house-bill/5376
[4]
Estimated Budgetary Effects of Public Law 117-169, to Provide for Reconciliation Pursuant to Title II of S. Con. Res. 14 https://www.cbo.gov/ publication/58455
[5]
The Inflation Reduction Act Lowers Health Care Costs for Millions of Americans https://www.cms.gov/newsroom/fact-sheets/inflation-reduction-act-lowers-health-care-costs-millions-americans
[6]
New HHS Reports Illustrate Potential Positive Impact of Inflation Reduction Act on Prescription Drug Prices https://www.hhs.gov/ about/news/2022/09/30/new-hhs-reports-illustrate-potential-positive-impact-inflation-reduction-act-prescription-drug-prices.html#:~:text=The%20average%20price%20increase%20for,size%20of%20drug%20price%20increases
[7]
Rome BN, Nagar S, Egilman AC, Wang J, Feldman WB, Kesselheim AS. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction
Act of 2022. JAMA Health Forum 2023; Jan 6;4(1): e225218.
[http://dx.doi.org/10.1001/jamahealthforum.2022.5218] [PMID: 36705916]
[http://dx.doi.org/10.1001/jamahealthforum.2022.5218] [PMID: 36705916]
[8]
Kaltenboeck A. “What the Inflation Reduction Act’s Reforms to Medicare Part D Mean for Prescription Drug Prices”, Health Affairs Forefront January
20, 2023.
[http://dx.doi.org/10.1377/FOREFRONT.20230119.156895]
[http://dx.doi.org/10.1377/FOREFRONT.20230119.156895]
[9]
Arad N, McClellan MB. “Drug Pricing Reform In The Inflation Reduction Act: What Are The Implications? Part 2”, Health Affairs Forefront,
December 15, 2022.
[http://dx.doi.org/10.1377/forefront.20221212.621957]
[http://dx.doi.org/10.1377/forefront.20221212.621957]
[10]
Cubanski J, Neuman T, and Freed M. Explaining the Prescription Drug Provisions in the Inflation Reduction Act. Jan 24, 2023 https://www.kff.org/medicare/issue-brief/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/
[11]
Nguyen Xuan Nguyen, Steven H Sheingold, Wafa Tarazi, Arielle Bosworth. Competition and Prices in Generic Drug Markets 2007- 2018 (Issue
Brief No. HP-2021-01). Washington, DC: Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services.
January 19, 2021.
[12]
Andrew W. Mulcahy, Preethi Rao, Vishnupriya Kareddy, Denis Agniel, Jonathan S. Levin, and Daniel Schwam. Assessing Relationships Between Drug Shortages in the United States and Other Countries. October 13, 2021. https://aspe.hhs.gov/reports/global-drug-shortages
Call for Papers in Thematic Issues
08 September, 2024
RARE CASES IN GYNECOLOGY-OBSTETRICS
With the development of diagnostic and therapeutic techniques (such as ART techniques) and the immersion of new pathologies (such as COVID19), we are witnessing an increase in the incidence of pathologies that were previously described as rare or exceptional. the practitioner sometimes confronts difficult situations in these cases in diagnostic ...read more
Article Metrics
17
2